Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
종목 코드 MGX
회사 이름Metagenomi Inc
상장일Feb 09, 2024
CEODr. Brian C. Thomas, Ph.D.
직원 수202
유형Ordinary Share
회계 연도 종료Feb 09
주소5959 Horton St
도시EMERYVILLE
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호94608
전화15108714880
웹사이트https://metagenomi.co/
종목 코드 MGX
상장일Feb 09, 2024
CEODr. Brian C. Thomas, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음